ATE466585T1 - Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation - Google Patents

Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation

Info

Publication number
ATE466585T1
ATE466585T1 AT02804652T AT02804652T ATE466585T1 AT E466585 T1 ATE466585 T1 AT E466585T1 AT 02804652 T AT02804652 T AT 02804652T AT 02804652 T AT02804652 T AT 02804652T AT E466585 T1 ATE466585 T1 AT E466585T1
Authority
AT
Austria
Prior art keywords
treatment
positive bacteria
immune
gram
diseases
Prior art date
Application number
AT02804652T
Other languages
English (en)
Inventor
Marie-Anne Nahori
Micheline Lagranderie
Gilles Marchal
Bernardo Vargaftig
Jean Lefort
Felix Romain
Georges Hekimian
Philippe Peltre
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE466585T1 publication Critical patent/ATE466585T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
AT02804652T 2001-12-11 2002-12-11 Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation ATE466585T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403195 2001-12-11
PCT/IB2002/005760 WO2003049752A2 (en) 2001-12-11 2002-12-11 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Publications (1)

Publication Number Publication Date
ATE466585T1 true ATE466585T1 (de) 2010-05-15

Family

ID=8183013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02804652T ATE466585T1 (de) 2001-12-11 2002-12-11 Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation

Country Status (18)

Country Link
US (3) US20060062807A1 (de)
EP (2) EP2316466B1 (de)
JP (2) JP4737586B2 (de)
KR (2) KR101124363B1 (de)
CN (1) CN1602199B (de)
AT (1) ATE466585T1 (de)
AU (1) AU2002356387C1 (de)
BR (1) BR0214902A (de)
CA (1) CA2469334C (de)
CY (1) CY1110727T1 (de)
DE (1) DE60236318D1 (de)
DK (2) DK2316466T3 (de)
ES (1) ES2345188T3 (de)
HK (1) HK1067073A1 (de)
NZ (2) NZ555055A (de)
PT (1) PT1461054E (de)
SI (1) SI1461054T1 (de)
WO (1) WO2003049752A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316466B1 (de) * 2001-12-11 2013-08-21 Institut Pasteur Behandlung von Immundysregulations-Erkrankungen mit einer Zusammensetzung aus Gram-positiven Bakterien
ES2471241T3 (es) * 2002-09-06 2014-06-25 Ucl Business Plc Células bacterianas completas como inmunomodulador
AR046583A1 (es) * 2003-11-14 2005-12-14 Ucl Biomedica Plc Uso de una composicion inmunomoduladora
WO2005080414A1 (en) 2004-02-19 2005-09-01 Ramot At Tel-Aviv University Ltd Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
CN101022826A (zh) * 2004-06-07 2007-08-22 哈罗尔·戴维·贡 用于癌症治疗的细菌组合物
DE602005017391D1 (de) 2004-06-24 2009-12-10 Yissum Res Dev Co Verwendung von peptid-mimotopen von mannosylierten lipoglycanen aus mycobacterien zur behandlung von entzündungen
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
NZ715882A (en) * 2006-10-27 2017-07-28 Qu Biologics Inc Tissue targeted antigenic activation of the immune response to treat cancers
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
EP2087898A1 (de) * 2008-02-06 2009-08-12 Institut Pasteur Herstellung des durch erweiterte Gefriertrocknung (EFD) abgetöteten Mycobakteriums bovis BCG zur Behandlung von rheumatoider Arthritis
CA2629057A1 (en) * 2008-04-14 2009-10-14 Institut Pasteur Control of diseases associated with decrease of t-regulatory cells with a preparation of extended freeze-dried killed bacteria
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
EP2292260A1 (de) 2009-08-13 2011-03-09 Institut Pasteur Verwendung des durch erweiterte Gefriertrocknung (EFD) abgetöteten Mycobakteriums bovis BCG zur Vorbeugung und Behandlung von Atherosklerose
EP2620159A1 (de) 2012-01-24 2013-07-31 Institut Pasteur Verbesserte Krebsbehandlung durch Immuntherapie mit BCG- oder antigenetisch ähnlichen nicht-pathogenen Mykobakterien
RU2724895C2 (ru) 2014-05-02 2020-06-26 Кью Байолоджикс Инк. Противомикробная иммуномодуляция
WO2017143386A1 (en) * 2016-02-25 2017-08-31 Borody Thomas J Compositions and methods of treatment of chronic infectious diseases
AU2019361036A1 (en) * 2018-10-17 2021-05-13 SciBac Inc. Live biotherapeutics to treat and prevent lung conditions
JP7441534B2 (ja) * 2019-01-09 2024-03-01 エムディー ヘルスケア インコーポレイテッド ロドコッカス属細菌由来ナノ小胞およびその用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594471A (en) * 1946-10-11 1952-04-29 Comb Eng Superheater Inc Heat exchange apparatus
GB764718A (en) * 1954-08-10 1957-01-02 Glaxo Lab Ltd Improvements in or relating to freeze-drying processes
GB1027979A (en) * 1963-07-12 1966-05-04 Ciba Ltd Process for obtaining bcg-cultures
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
JPS57186495A (en) * 1981-05-14 1982-11-16 Ube Ind Ltd Preparation of l-alpha-methylphenylalanine
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
IN164864B (de) 1985-05-13 1989-06-24 Commw Scient Ind Res Org
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPS63126830A (ja) * 1986-11-17 1988-05-30 Isao Moriya 動植物の体内に抗体を生成する方法
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
US6350457B1 (en) 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
EP2316466B1 (de) 2001-12-11 2013-08-21 Institut Pasteur Behandlung von Immundysregulations-Erkrankungen mit einer Zusammensetzung aus Gram-positiven Bakterien

Also Published As

Publication number Publication date
BR0214902A (pt) 2004-11-30
JP5417354B2 (ja) 2014-02-12
CY1110727T1 (el) 2015-06-10
NZ533422A (en) 2008-03-28
CA2469334C (en) 2012-05-08
NZ555055A (en) 2010-06-25
HK1067073A1 (en) 2005-04-01
AU2002356387B2 (en) 2007-09-13
KR20040080434A (ko) 2004-09-18
EP1461054A2 (de) 2004-09-29
ES2345188T3 (es) 2010-09-17
EP2316466A2 (de) 2011-05-04
EP1461054B1 (de) 2010-05-05
AU2002356387A1 (en) 2003-06-23
CA2469334A1 (en) 2003-06-19
DE60236318D1 (de) 2010-06-17
PT1461054E (pt) 2010-08-09
DK2316466T3 (da) 2013-11-18
EP2316466A3 (de) 2012-04-11
WO2003049752A3 (en) 2003-11-20
AU2002356387C1 (en) 2008-03-06
SI1461054T1 (sl) 2010-09-30
JP4737586B2 (ja) 2011-08-03
US20100272756A1 (en) 2010-10-28
DK1461054T3 (da) 2010-08-16
KR20110028558A (ko) 2011-03-18
JP2005516915A (ja) 2005-06-09
US20070190076A1 (en) 2007-08-16
CN1602199A (zh) 2005-03-30
EP2316466B1 (de) 2013-08-21
US20060062807A1 (en) 2006-03-23
KR101048798B1 (ko) 2011-07-15
US7871627B2 (en) 2011-01-18
JP2011121977A (ja) 2011-06-23
CN1602199B (zh) 2012-04-04
KR101124363B1 (ko) 2012-03-21
WO2003049752A2 (en) 2003-06-19
US8404250B2 (en) 2013-03-26

Similar Documents

Publication Publication Date Title
HK1067073A1 (en) Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
WO2001090129A3 (en) Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
HK1048831A1 (en) Human ctla-4 antibodies and their uses
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
EP1262177A3 (de) Medizinische Verwendung thyromimetischer Verbindungen gegen Haarausfall und Zusammensetzungen
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
WO2003063725A3 (en) Methods of preventing and treating flavivirus infection in animals
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
WO2003024996A3 (de) Antibakterielle makrozyklen
DE60231994D1 (de) Mittel zur behandlung oder prävention allergischerg
WO2002011549A3 (en) Treatment of mycobacterial infection
ATE390144T1 (de) Behandlung von fibrosen
DE69618813T2 (de) Bismut und antimikrobielle mittel enthaltende zusammensetzung zur verhütung und behandlung gastrointestinaler beschwerden
EP1498145A4 (de) LOCKSTOFF ZUR BEHANDLUNG UND/ODER PRÄVENTION VON Th2 CYTOKIN-ASSOZIIERTEN ALLERGISCHEN ERKRANKUNGEN, GATA3 MUTANT-PROTEIN UND DIESES ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN
WO2003022881A3 (de) Phänotyp bestimmende virulenzgene von pseudomonas aeruginosa zur kolonisation und persistenz in mensch, tier und pflanze, verwendungen der gene und zugehörigen proteine
WO2003053959A8 (de) Heterocyclylaminocarbo nyluracile
WO2006081372A3 (en) Use of parasitic biological agents for prevention and control of allergic and other ige-mediated disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1461054

Country of ref document: EP